Key takeaway
Legal challenges to the UWWTD from 14 pharmaceutical firms spotlight growing tensions around extended producer responsibility. The outcomes could reshape how environmental costs are shared across the chemicals and manufacturing ecosystem.
They argue that the directive imposes unfair financial burdens, was adopted under the wrong legal basis, and risks limiting drug availability. The lawsuits aim to annul parts of the directive or its entirety.
A coalition of fourteen pharmaceutical companies has filed lawsuits against the European Union’s Urban Wastewater Treatment Directive (UWWTD), adopted in November 2024. The legal actions, lodged in March 2025 before the General Court of the European Union, argue that the directive imposes disproportionate financial burdens on medicinal and cosmetic product manufacturers, potentially setting a precedent for extended producer responsibility (EPR) across multiple sectors.
The contested UWWTD mandates quaternary treatment upgrades in urban wastewater plants to remove micropollutants, including pharmaceutical residues. Articles 9 and 10 of the directive establish an EPR scheme requiring relevant producers to cover up to 100% of associated costs. Pharmaceutical firms assert this policy violates legal and procedural norms under EU law, and that it targets their sector unfairly.
Plaintiffs such as Accord Healthcare, Zentiva, Teva, and Laboratorios Normon claim the directive was adopted using an incorrect legal basis under Article 192(1) of the Treaty on the Functioning of the European Union (TFEU), which applies to environmental matters. They argue that due to the fiscal nature of the obligations, Article 192(2)(a)—requiring unanimous Council approval—should have been used.
Beyond legal technicalities, the lawsuits underscore broader concerns about regulatory fairness and cost distribution. Producers argue the EPR scheme lacks clarity on implementation, including cost calculation methods and criteria for exemptions (e.g., “rapidly biodegradable” substances). Industry stakeholders also fear unintended consequences for public health, as the directive could disincentivise the development of vital pharmaceuticals, particularly where structural redesign of active ingredients is not viable.
Although no trade associations have joined the legal action, the coordinated filings suggest widespread concern across the sector. These cases will likely influence how future EU environmental regulations allocate responsibilities among stakeholders in pharmaceuticals, cosmetics, and beyond.
A ruling by the General Court could redefine the scope of EPR obligations in EU legislation, shaping future compliance expectations for chemical-intensive industries. Companies across the manufacturing value chain should monitor developments closely and evaluate potential operational and legal impacts.
Directive (EU) 2026/805 strengthens EU water protection by expanding controls on PFAS, pharmaceuticals, bisphenols and emerging pollutants. The rules increase monitoring expectations, sharpen future quality standards and give ECHA a larger scientific role, creating new compliance considerations across chemicals, manufacturing, water treatment and downstream sectors.
The FDA will require ICH E2B(R3) data standards for electronic safety reporting from October 2026. The change enhances data quality and global harmonisation but requires significant system upgrades. Stakeholders across the pharmaceutical value chain must act early to ensure compliance and avoid regulatory risk.
ECHA assesses tert-alkyl/aryl peroxyesters for reproductive and aquatic toxicity risks, urging regulatory actions.
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
